🔗 Share this article

While America undertakes unprecedented revisions to its immunization recommendations, one figure has emerged unexpectedly: Tracy Beth Høeg, a US-based sports physician and epidemiologist who initially gained attention by expressing skepticism about coronavirus shots during the pandemic and has zeroed in on possible deaths following Covid immunization in her short tenure at the US Food and Drug Administration (FDA).

Proposed Changes to Pediatric Immunization Schedule

Health officials were set to unveil radical changes to the pediatric vaccine schedule recently, bringing the US with the Danish immunization schedule, sources say – a substantial departure that would place the US at odds with many the global community with little proof for benefit. The planned update has been delayed until the coming year.

Instead of the director of the vaccine center, Høeg is scheduled to present at the event. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the division this year.

A New Direction at the Agency

This interim role may indicate a strengthened alliance between the drug and vaccine divisions as Dr. Høeg and Prasad consolidate power at the FDA – and it signals a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

Dr. Høeg has frequently advocated for halting some pediatric vaccine recommendations in the US to become more similar to Denmark, a nation with comprehensive healthcare and a citizenry roughly the population of Wisconsin’s.

To date public appearances, she has persisted in emphasizing on vaccination policy – traditionally the purview of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Questions Over Expertise

The appointee has no apparent background in drug development, approval processes or management, which has been customary for previous heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since March.

“It seems she lacks to have the requisite experience” for overseeing the drug-regulation department, said Dr. Jonathan Howard. “She’s never run a clinical trial. She lacks experience in leading a large organization. She has no expertise in drug approvals.”

Past heads of CBER would “grasp regulatory frameworks and the underlying principles of pharmaceutical innovation”, said Dr. Janet Woodcock. “Clearly, she lacks the sort of resume that previous people who headed CBER have had.”

This division has an immense portfolio at the agency, Woodcock pointed out.

“The public just pays attention on the innovative therapies, but the off-patent medication office authorizes thousands of generic medications. There is also a biosimilars program, non-prescription drug unit and so forth, and each of these need to be looked after,” she noted. “The area you neglect, that is precisely what that I always told people is going to cause problems.”

Additionally, a substantial administrative aspect to the job, which manages over 5,000 staff members. “It’s a enormous leadership role, if you do it right,” she added.

Agency Reaction and Disputed Programs

In response to concerns about Høeg’s credentials and whether this appointment indicates increased cooperation among agency officials on vaccines, a press secretary stated that the “concerns stem from inaccurate premises”.

“Her experience is consistent with the responsibilities of her role,” the representative explained, noting the time Dr. Høeg spent guiding the agency head on “pharmaceutical safety and regulatory science, including computational safety modeling and vaccine surveillance”.

In her interim role, Høeg takes over the agency head's new expedited review system, a controversial one-day drug-approval program that allegedly worried her preceding directors. “By what process are these medications being selected for this voucher program? Who takes the decisions?” Howard said. “There is a lot of secrecy happening at the agency right now.”

In general, he said, “the Food and Drug Administration seems to be moving towards more relaxed rules of most medications, aside from vaccines.”

Documented Past Work on Vaccines

Concerning immunizations, Dr. Høeg has a more established, if concerning, history, Howard observe. She published a research paper using unverified crowd-sourced reports to assess the frequency of myocarditis after COVID-19 immunization. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to suggest Covid vaccinations are riskier than they are.

Part of her “desired changes” for the current administration encompassed revising regulations for new vaccines and halting “non-essential” immunizations, she remarked after the election on a podcast. At the FDA, Høeg has reportedly suggested barring young men from getting Covid vaccines.

“She’s an thorough dogmatist who starts off with her preconceived notions and tailors the evidence to fit the science in a very disingenuous, fraudulent way,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined other skeptics, {like|